Preview

Рецепт

Расширенный поиск

Особенности ведения заболеваний периферических артерий нижних конечностей при сахарном диабете

https://doi.org/10.34883/PI.2021.24.3.003

Полный текст:

Аннотация

Сахарный диабет – признанный фактор риска мультисосудистого поражения, развития полинейропатии, когнитивного снижения. Заболевания периферических артерий нижних конечностей (ЗПАНК) являются частым проявлением при сахарном диабете, определяя негативный прогноз. В обзоре рассмотрены современные подходы к ведению пациентов с ЗПАНК, включая особенности использования глюкозоснижающей терапии, гипотензивных и гиполипидемических препаратов с превентивной целью. Четко обоснована необходимость использования физических нагрузок, описаны возможности терапевтического лечения. Среди терапевтических опций сделан акцент на потенциальные преимущества использования актовегина, оказывающего мультимодальное действие.

Об авторе

Т. В. Мохорт
Белорусский государственный медицинский университет
Беларусь

Минск



Список литературы

1. Criqui MH, Aboyans V Epidemiology of Peripheral Artery Disease. Circ Res. 2015; 116: 1509–1526.

2. Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, et al Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015; 61(3 Suppl): 2S–41S.

3. Szymczak-Pajor I, Śliwińska A. Analysis of Association between Vitamin D Deficiency and Insulin Resistance. Nutrients. 2019; 11(4): 794. doi: 10.3390/nu11040794

4. Greenhagen RM. Serum vitamin D and diabetic foot complications. Diabet Foot Ankle. 2019; 10(1): 1579631. doi: 10.1080/2000625X.2019.1579631

5. Shepelkevich AP et al Vibration sensitivity violation evaluation for diabetic distal polyneuropathy early diagnosis in patients with type 2 diabetes. Diabetologia (2015) 58 (Suppl 1): S1–S607.

6. Pfannkuche A, Alhajjar A. Prevalence and risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative “diabetes and nerves”. Endocrine and Metabolic Science 2020; 1 (1–2): 100053. Available at: https://doi.org/10.1016/j.endmts.2020.100053

7. Galstyan G.R. Zabolevaniya arterij nizhnih konechnostej u pacientov s saharnym diabetom: sostoyanie problemy i perspektivy lecheniya [Diseases of the arteries of the lower extremities in patients with diabetes mellitus: state of the problem and prospects of treatment]. Saharnyj diabet. 2011 (1), 74–79.

8. IDF Clinical Practice Recommendations on the Diabetic Foot – 2017/IDF, 2017.

9. Cosentino F, Grant PJ. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal (2020) 41, 255323.

10. Standards of Medical Care in Diabetes – 2021 American Diabetes Association. Diabetes Care 2021; 44(Supplement 1): S125–S167.

11. Hennrikus D. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J. Am. Coll. Cardiol. Elsevier BV, 2010; 56 (25): 2105–2112.

12. Rigotti NA. (2010) Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial. Circulation. Ovid Technologies (Wolters Kluwer Health), 2010; 121 (2): 221–229.

13. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 2010; 299: F14–F25.

14. Yamagishi SI. Glycation and cardiovascular disease in diabetes: a perspective on the concept of metabolic memory. J Diabetes, 2017; 9:141–148.

15. Dekker RG, Qin C. The effect of cumulative glycemic burden on the incidence of diabetic foot disease. J Orthop Surg Res., 2016; 11:143.

16. Cosentino F. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart Journal, 2020; 41 (2): 255–323.

17. Dedov I.I., Shestakova M.V. (2019) Algoritmy specializirovannoj medicinskoj pomoshchi bol'nym saharnym diabetom [Algorithms of the specialized medical care for patients with diabetes mellitus]. Vip. 9.

18. Verma S. (2020) Liraglutide and semaglutide reduce cardiovascular events in patients with type 2 diabetes and peripheral arterial disease EASD 2020. Abstract #590 https://www.easd.org.

19. Matthews DR. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia, 2019; 62: 926–938.

20. Miyashita S. (2020) Risk of Amputation Associated with Sodium-Glucose Co-Transporter 2 Inhibitors: A Meta-Analysis of Five Randomized Controlled Trials. Diabetes Research and Clinical Practice, 2020. doi: 10.1016/j.diabres.2020.108136

21. Dagenais GR. Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial. Diabetes Obes Metab, 2019; 21(6): 1502–1505.

22. Yusuf S. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. NEJM, 2000; 342: 145–153.

23. Yusuf S. Telmisartan, ramipril, or both in patients at high risk for vascular events. NEJM, 2008; 358: 1547–1559.

24. Diehm C. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J. Hypertens. Ovid Technologies (Wolters Kluwer Health), 2011, vol. 29, no 7, pp. 1448–1456.

25. Paravastu SCV. Beta blockers for peripheral arterial disease. Cochrane Database Syst. Rev. Wiley-Blackwell, 2013.

26. De Buyzere ML. Management of Hypertension in Peripheral Arterial Disease. Prog. Cardiovasc. Dis. Elsevier BV, 2008; 50 (4): 238–263.

27. Keech AC. FIELD study investigators. Lancet. 2007; 370(9600): 1687–1697.

28. Watson L. Exercise for intermittent claudication. Cochrane Database Syst Rev 2008 8;(4):CD000990.

29. Hageman D. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev. 2018;4(4):CD005263.

30. Lane R. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017;12(12): CD000990.

31. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. J Vasc Surg, 2015; 61: 2S–41S.

32. De Backer TL. Cochrane Database Syst Rev. 2012; 12; 12(12): CD001368.

33. Buchmayer F. Actovegin: a biological drug for more than 5 decades. Wien Med Wochenschr, 2011; 161/3–4: 80–88.

34. Elmlinger MW. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro. Neuromolecular Med. 2011; 13(4): 266–274.

35. Machicao F. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. Neurol Sci, 2012; 322 (1–2): 222–227.

36. Ziegler D. Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients Diabetes Care, 2009; 32(8): 1479–1484.

37. Guekht A. ARTEMIDA trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017; 48: 1262–1270.

38. Strachan MWJ. The relationship between type 2 diabetes and dementia. British Medical Bulletin. 2008; 88: 131–146.

39. Angelkort B. Stoffwechselaktiver Kälberblutextrakt bei austrainierten Patienten mit AVK im Stadium II – Eine Placebo-kontrollierte Doppelblindstudie. Vasa, 1988; Suppl 23: 141–143.

40. Horsch S. Assessment of the clinical effectiveness of actihaemyl in Fontaine stage IIb intermittent claudication. Vasa Suppl., 1992; 37: 64–65.

41. Müller-Bühl U. Gehstreckenzuwachs durch intraarteriell verabreichtes Hämodialysat. Therapiewoche, 1991; 4:188–196.

42. Gurieva I.V. i dr Patogeneticheskoe lechenie Aktoveginom nejroishemicheskogo bolevogo sindroma v nizhnih konechnostyah pri saharnom diabete. RMZh. 2009; 10(349): 670–6722yu

43. Losev R.Z. Hirurgicheskoe lechenie pacientov s sindromom diabeticheskoj stopy [Surgical treatment of patients with diabetic foot syndrome]. RMZh. 2010; 14: 924.

44. Anikin A.I. Kompleksnoe hirurgicheskoe lechenie bol'nyh s gnojno-nekroticheskimi porazheniyami na fone sindroma diabeticheskoj stopy [Complex surgical treatment of patients with purulent-necrotic lesions on the background of diabetic foot syndrome]. RMZh. 2010; 17: 1055–1059.

45. Sviridov N.V. Vnutriarterial'noe ispol'zovanie Aktovegina v kompleksnom lechenii destruktivnyh form diabeticheskoj stopy [Intra-arterial use of Actovegin in complex treatment of destructive forms of diabetic foot]. Hirurgiya Ukrainy. 2009; 2: 73–77.

46. Dibirov M.D. Opyt primeneniya aktovegina v lechenii nejroishemicheskoj formy sindroma «diabeticheskaya stopa» [Experience of use of actovegin in treatment of neuroischemic form of diabetic foot syndrome]. Famateka, 2014; 20: 54–58.

47. Uchkin I.G. Vliyanie farmakoterapii hronicheskih obliteriruyushchih zabolevanij arterij nizhnih konechnostej na sostoyanie mikrocirkulyatornogo rusla [Influence of pharmacotherapy of chronic obliterating diseases of arteries of the lower extremities on the state of microcircular bed]. Angiologiya i sosudistaya hirurgiya, 2014; 20 (2): 27–36.

48. Lane R. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews, 2017; 12: Art. No.: CD000990. DOI: 10.1002/14651858.CD000990.pub4

49. Nacional'nye rekomendacii RF (2019) po diagnostike i lecheniyu zabolevanij arterij nizhnih konechnostej [National recommendations of the RF (2019) on diagnostics and treatment of diseases of the arteries of lower extremities].

50. Fedorovich AA. Non-invasive evaluation of vasomotor and metabolic functions of microvascular endothelium in human skin. Microvasc Res., 2012; 84: 86–93.

51. Tanashyan A.A. Mul'timodal'nyj podhod k korrekcii nevrologicheskih proyavlenij hronicheskoj ishemii mozga [Multimodal approach to correction of neurological manifestations of chronic brain ischemia]. Terapevticheskij arhiv. 2018; 12: 61–67.

52. ClinicalTrials.gov Identifier: NCT03469349 https://clinicaltrials.gov/ct2/show/NCT03469349?term=actovegin&draw=2&rank


Для цитирования:


Мохорт Т.В. Особенности ведения заболеваний периферических артерий нижних конечностей при сахарном диабете. Рецепт. 2021;(3):332-344. https://doi.org/10.34883/PI.2021.24.3.003

For citation:


Mokhort T. Features of Management of Peripheral Arterial Disease of the Lower Extremities in Diabetes Mellitus. Recipe. 2021;(3):332-344. (In Russ.) https://doi.org/10.34883/PI.2021.24.3.003

Просмотров: 78


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)